Table 2.
Comparison of demographic, clinical characteristics, and treatments of patients at the time of flare between those who received or did not receive anakinra.
| Variable | No Anakinra | Anakinra | p-Value |
|---|---|---|---|
| N = 367 | N = 18 | ||
| Gender | |||
| Male | 210 (57.22%) | 9 (50.0%) | 0.629 |
| Women | 157 (42.78%) | 9 (50.0%) | |
| N = 367 | N = 18 | ||
| Age at first symptoms (years) | 8.56 (± 4.44) | 10.06 (± 3.97) | 0.168 |
| N = 365 | N = 18 | ||
| Ethnicity | |||
| african_west_indies | 1 (0.88%) | 0 (0.0%) | 0.587 |
| asia | 3 (2.63%) | 0 (0.0%) | |
| caucasians | 34 (29.82%) | 1 (25.0%) | |
| mediterranean_basin | 30 (26.32%) | 3 (75.0%) | |
| mixed | 9 (7.89%) | 0 (0.0%) | |
| north_central_america | 2 (1.75%) | 0 (0.0%) | |
| sub_saharan_africa | 30 (26.32%) | 0 (0.0%) | |
| unknown | 5 (4.39%) | 0 (0.0%) | |
| N = 114 | N = 4 | ||
| Total hospitalization time (days) | 9.38 (± 19.58) | 17.24 (± 16.91) | <0 . 001 |
| N = 365 | N = 17 | ||
| Symptoms of initial acute flare | |||
| Irritability | 79 (42.25%) | 10 (90.91%) | 0 . 03 |
| Yes | 108 (57.75%) | 1 (9.09%) | |
| No | N = 187 | N = 11 | |
| Deterioration of general condition | 283 (94.33%) | 15 (100.0%) | >0.999 |
| Yes | 17 (5.67%) | 0 (0.0%) | |
| No | N = 300 | N = 15 | |
| Musculoskeletal manifestation | 62 (22.55%) | 5 (33.33%) | 0.349 |
| Yes | 213 (77.45%) | 10 (66.67%) | |
| No | N = 275 | N = 15 | |
| Cutaneous manifestation | 253 (77.85%) | 15 (88.24%) | 0.544 |
| Yes | 72 (22.15%) | 2 (11.76%) | |
| No | N = 325 | N = 17 | |
| Respiratory manifestation | 99 (34.74%) | 8 (53.33%) | 0.17 |
| Yes | 186 (65.26%) | 7 (46.67%) | |
| No | N = 285 | N = 15 | |
| Digestive manifestation | 275 (83.08%) | 14 (82.35%) | >0.999 |
| Yes | 56 (16.92%) | 3 (17.65%) | |
| No | N = 331 | N = 17 | |
| Ocular manifestation | 178 (59.73%) | 11 (64.71%) | 0.802 |
| Yes | 120 (40.27%) | 6 (35.29%) | |
| No | N = 298 | N = 17 | |
| Vascular manifestation | 10 (3.65%) | 2 (13.33%) | 0.123 |
| Yes | 264 (96.35%) | 13 (86.67%) | |
| No | N = 274 | N = 15 | |
| Cardiac manifestation | 247 (82.33%) | 15 (93.75%) | 0.324 |
| Yes | 53 (17.67%) | 1 (6.25%) | |
| No | N = 300 | N = 16 | |
| Initial CRP (mg/L) | 124.28 (± 94.89) | 176.83 (± 92.1) | 0.08 |
| N = 99 | N = 10 | ||
| CRP max (mg/L) | 235.76 (± 104.78) | 257.31 (± 125.14) | 0.606 |
| N = 224 | N = 10 | ||
| ALAT max (UI/L) | 68.42 (± 71.68) | 85.06 (± 59.97) | 0.118 |
| N = 204 | N = 13 | ||
| ASAT max (UI/L) | 84.16 (± 88.92) | 69.08 (± 67.1) | 0.358 |
| N = 202 | N = 12 | ||
| Ferritin max (µg/L) | 401,418.06 (± 985,141.88) | 417,654.45 (± 644,059.57) | 0.419 |
| N = 186 | N = 11 | ||
| Nt-proBNP max (ng/L) | 16,827.39 (± 88,506.54) | 13,961.54 (± 15,906.99) | 0.229 |
| N = 186 | N = 13 | ||
| Troponine max (ng/L) | 17,66,726.92 (± 25,653,463.86) | 142.73 (± 167.67) | 0.582 |
| N = 246 | N = 10 | ||
| Ferritin max (µg/L) | |||
| LVEF (%) | 50.55 (± 12.6) | 43.0 (± 10.95) | 0.208 |
| 95% CI: (46.57; 54.53) | 95% CI: (29.4; 56.6) | ||
| N = 41 | N = 5 | ||
| Corticotherapy treatment | 267 (72.75%) | 14 (77.78%) | 0.789 |
| Yes | 100 (27.25%) | 4 (22.22%) | |
| No | N = 367 | N = 18 | |
| Total corticotherapy duration (days) | 5.79 (± 4.1) | 10.64 (± 6.01) | <0 . 001 |
| N = 367 | N = 14 | ||
| IVIG treatment | |||
| Yes | 280 (76.29%) | 10 (55.56%) | 0.088 |
| No | 87 (23.71%) | 8 (44.44%) | |
| N = 367 | N = 18 | ||
| IVIG adverse event | |||
| Yes | 0 (0%) | 1 (10%) | 0 . 034 |
| No | 280 (100%) | 9 (90%) | |
| N = 280 | N = 10 | ||
| Beta-blocker treatment | |||
| Yes | 13 (3.54%) | 3 (16.67%) | 0 . 033 |
| No | 354 (96.4%) | 15 (83.33%) | |
| N = 367 | N = 18 | ||
Bold values denote statistical significance (p < 0.05).